Eyepoint Pharmaceuticals earnings were -$130.9M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest EYPT earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$41.4M, up 41% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, EYPT reported annual earnings of -$130.9M, with 84.9% growth. The next EYPT earnings date is May 6, 2025.
Eyepoint Pharmaceuticals Earnings Reports & History FAQ
What were Eyepoint Pharmaceuticals's earnings last quarter?
On EYPT's earnings call on Invalid Date, Eyepoint Pharmaceuticals (NASDAQ: EYPT) reported Q4 2024 earnings per share (EPS) of -$0.65, up 103.13% year over year. Total EYPT earnings for the quarter were -$41.40 million. In the same quarter last year, Eyepoint Pharmaceuticals's earnings per share (EPS) was -$0.32.
When does Eyepoint Pharmaceuticals report earnings?
The next EYPT earnings call is Invalid Date. Add EYPT to your watchlist to be reminded of Eyepoint Pharmaceuticals's next earnings date.
Is Eyepoint Pharmaceuticals profitable or losing money?
As of the last Eyepoint Pharmaceuticals earnings report, Eyepoint Pharmaceuticals is currently losing money. Eyepoint Pharmaceuticals's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$130.87 million, a 84.86% increase year over year.
What was EYPT's earnings growth in the past year?
As of Eyepoint Pharmaceuticals's earnings date in Invalid Date, Eyepoint Pharmaceuticals's earnings has grown year over year. EYPT earnings in the past year totalled -$130.87 million.
What are Eyepoint Pharmaceuticals's earnings expectations?
The current EPS estimate for Eyepoint Pharmaceuticals's earnings report in Invalid Date is -$0.41.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.